

## FRIDAY 12 September

10.00	Registration, refreshments, exhibition and poster viewing
11.00-12.30	Welcome Amit Bahl, Chair, BUG
	Uro-oncology Round up
	Prostate systemic therapy Anuradha Jayaram, Consultant Medical
	Oncologist, University College London
	• Prostate radiation therapy Joe O'Sullivan, Professor of Radiation Oncology,
	Queen's University Belfast
	Bladder Simon Crabb, Professor of Experimental Cancer Therapeutics,
	University of Southampton
	Renal Lisa Pickering, Consultant Medical Oncologist, The Royal Marsden
	NHS Foundation Trust
	Testicular speaker tba
	• Penile EPIC Amit Bahl, Consultant Clinical Oncologist, Bristol Haematology
	& Oncology Centre
12.30	Lunch, exhibition and poster viewing
13.30-14.30	Seminar sessions 1
1A	Where do you stand on ARPI plus PARPI?
	Chair: Simon Crabb, Professor of Experimental Cancer Therapeutics,
	University of Southampton
	Rob Jones, Senior Lecturer & Honorary Consultant, The Beatson West of
	Scotland Cancer Centre, Glasgow
	Anna Wilkins, Consultant Clinical Oncologist, Institute of Cancer Research
1B	Survivorship in Uro-oncology
	Chair: Robert Huddart, Professor and Honorary Consultant in Urological
	Oncology, Institute of Cancer Research
	• Diet and dietary modification in care of prostate cancer <i>Robert Thomas</i> ,
	Consultant Oncologist, Addenbrooke's, Bedford, UCLH
	The value of exercise in Urological cancer survivors speaker tba
	• The value of Holistic care in testicular and prostate survivors <i>Rob Holwell</i> ,
	GP with extended role, Royal Marsden
1C	Update in mRCC management: a case based discussion
	Chair: Amarnath Challapalli, Consultant Clinical Oncologist, Bristol Cancer
	Institute
	The role of SABR in primary RCC Anjali Zarkar, Consultant Clinical
	Oncologist, University Hospitals Birmingham
	Belzutifan in VHL cases Balaji Venugopal, Consultant in Medical Oncology,
	Beatson West of Scotland Cancer Centre, Glasgow
	Post adjuvant Pembro failures and Tx choices Amarnath Challapalli,
	Consultant Clinical Oncologist, Bristol Cancer Institute



14.30-15.30	The future of AI
	Chair: Rob Jones, Senior Lecturer & Honorary Consultant, The Beatson West of
	Scotland Cancer Centre, Glasgow
	Dummies guide to AI and Machine Learning Robert Insall, Professor of
	Computational Cell Biology, University College London
	The role of AI in Radiotherapy Alan McWilliam, Reader, University of Manchester
	• Clare Verrill, Professor of Cellular Pathology and Artificial Intelligence,
	University of Oxford
15.30	Refreshments, exhibition and poster viewing
16.00	Urothelial cancer rapid fire debates with voting
	Chair: Simon Hughes, Consultant Clinical Oncologist, Guy's & St Thomas' NHS
	Foundation Trust
	• The patient's perspective Melanie Costin, Director of Patient
	Engagement & Support, Fight Bladder Cancer
	1. Upper tract disease: systemic treatment, when's the right time
	Neoadjuvant Jim Catto, Professor of Urology, University of Sheffield
	Adjuvant Alison Birtle, Honorary Clinical Professor & Consultant
	Oncologist, Rosemere Cancer Centre
	2. NMIBC – my option is better than yours
	<ul> <li>Intravesical/surgery Jonathan Aning, Consultant Urological Surgeon, North Bristol NHS Trust</li> </ul>
	• RT Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS
	Foundation Trust and University of Manchester
	Systemic Dominque Parslow, Consultant Clinical Oncologist,
	University Hospitals Plymouth NHS Trust
	3. Node positive Muscle invasive bladder cancer with good response to
	chemotherapy- what's the next step
	• Systemic + surgery Krishna Narahari, Consultant Urological Surgeon &
	Honorary Senior Lecturer at Cardiff & vale University Health Board
	• Systemic + RT Martin Swinton, The Christie NHS Foundation Trust,
	Manchester
	Systemic alone Hilary Glen, Consultant Medical Oncologist, The
	Beatson West of Scotland Cancer Centre, Glasgow
17.00	Why should you look at my poster?
	Chair: Mark Beresford, Consultant Oncologist, Royal United Hospital, Bath
	One minute presentations from each poster author
17.30-18.15	Welcome reception, exhibition and top 5 poster tour
19.30	Predinner drinks
20.00	Conference dinner



## SATURDAY 13 September

08.15	Registration, refreshments, exhibition and poster viewing
08.45-09.15	BUG AGM
	Review of 2024/2025 activity
	Members only
09.15-10.15	National audits update
	Chair: Amit Bahl, Chair, BUG
	NPCA. Alison Tree, Consultant Clinical Oncologist, The Royal Marsden NHS
	Foundation Trust
	NKCA. Raghav Varma, ST6 Urology Trainee, Royal College of Surgeons / The
	London School of Hygiene & Tropical Medicine
	Bladder: RCR MIBIC Reaudit Mohini Varughese, Consultant Clinical
	Oncologist, Royal Devon University Hospitals NHS Foundation Trust
10.15	Helen Patterson Award for Registrar Research
	Chair: Robert Huddart, Professor and Honorary Consultant in Urological
10.45	Oncology, Institute of Cancer Research
10.15	Chair's welcome
10.20	2024 Winner's presentation Nicola Hill, Northern Ireland Cancer Centre, Belfast
10.25	Presentations
10.25	riesentations
11.00-11.30	Refreshments, exhibition and poster viewing
	-
11.30-12.45	Seminar sessions 2
<b>11.30-12.45</b> 2A	Seminar sessions 2 Bladder cancer - when what we give today might determine what we give
	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging,
	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues
	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues Chairs: Alison Birtle, Honorary Clinical Professor & Consultant Oncologist,
	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues Chairs: Alison Birtle, Honorary Clinical Professor & Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical
	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues Chairs: Alison Birtle, Honorary Clinical Professor & Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester
	Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues Chairs: Alison Birtle, Honorary Clinical Professor & Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:
	Bladder cancer - when what we give today might determine what we givetomorrow- one patient's journey from muscle invasive to metastaticbladder cancer to include controversies on treatment, imaging,biomarkers, histological subtypes and sequencing issuesChairs: Alison Birtle, Honorary Clinical Professor & Consultant Oncologist,Rosemere Cancer Centre and Ananya Choudhury, Professor of ClinicalOncology, The Christie NHS Foundation Trust and University of ManchesterPanel:• Simon Crabb, Professor of Experimental Cancer Therapeutics, University of
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester</li> <li>Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> <li>Niyati Lobo, Consultant Urological Surgeon, Cambridge University</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> <li>Niyati Lobo, Consultant Urological Surgeon, Cambridge University Hospitals NHS Foundation Trust</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> <li>Niyati Lobo, Consultant Urological Surgeon, Cambridge University Hospitals NHS Foundation Trust</li> <li>Phillipe Taniere, Consultant Histopathologist/Molecular Pathology,</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> <li>Niyati Lobo, Consultant Urological Surgeon, Cambridge University Hospitals NHS Foundation Trust</li> <li>Phillipe Taniere, Consultant Histopathologist/Molecular Pathology, Birmingham</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> <li>Niyati Lobo, Consultant Urological Surgeon, Cambridge University Hospitals NHS Foundation Trust</li> <li>Phillipe Taniere, Consultant Histopathologist/Molecular Pathology, Birmingham</li> <li>Rashid Amir, Consultant Abdominal Radiologist, Queen Elizabeth Hospital</li> </ul>
	<ul> <li>Bladder cancer - when what we give today might determine what we give tomorrow- one patient's journey from muscle invasive to metastatic bladder cancer to include controversies on treatment, imaging, biomarkers, histological subtypes and sequencing issues</li> <li>Chairs: Alison Birtle, Honorary Clinical Professor &amp; Consultant Oncologist, Rosemere Cancer Centre and Ananya Choudhury, Professor of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester Panel:</li> <li>Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton</li> <li>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</li> <li>Niyati Lobo, Consultant Urological Surgeon, Cambridge University Hospitals NHS Foundation Trust</li> <li>Phillipe Taniere, Consultant Histopathologist/Molecular Pathology, Birmingham</li> </ul>



2B	<ul> <li>Imaging in Prostate Cancer Management</li> <li>Chair: Suneil Jain, Consultant Clinical Oncologist, Queen's University, Belfast</li> <li>Staging, BCR, oligometastases Tara Barwick, Consultant Radiologist and Professor of Practice (Cancer Imaging), Imperial College Healthcare NHS Trust</li> <li>Response assessment and theranostics Sairah Khan, Imperial College Healthcare NHS Trust</li> <li>Whole body MRI Anwar Padhani, Consultant Radiologist and Professor of Cancer Imaging, Paul Strickland Scanner Centre</li> </ul>
2C	<ul> <li>When things go wrong</li> <li>Chair: Rob Jones, Senior Lecturer &amp; Honorary Consultant, The Beatson West of Scotland Cancer Centre, Glasgow</li> <li>Case based legal discussions/Coroner's inquest/Legal aspects</li> <li>Jeremy Roussak, Barrister, Kings Chambers, Manchester</li> <li>Peter Hoskin, Consultant Uro-Oncologist, The Christie NHS Foundation Trust</li> </ul>
12.45	Closing session Chair <i>Amit Bahl, Chair BUG</i> Prize giving Helen Patterson Award for registrar research Best poster prize
13.00-14.15	Lunch and depart

## The sponsors have had no input or influence on the agenda or programme content for this meeting.